The sector continues to plod along. I think there is some interesting news with the oral GLP launch and while it certainly has import for the companies involved, I think the sector does best when there is a big launch that creates buzz outside the sector. It is the generalists that really push bull markets […]
January 20th Biotech Update
Heading into JPM, the sector was navigating a transition from volatility toward selective strength. After a challenging 2025 for venture funding and IPO activity, investors showed cautious optimism driven by increased M&A and improved clinical pipelines. Large pharmas continued to balance patent cliffs with new launches, while emerging biotech companies emphasized differentiated platforms in oncology, […]
January 9th Biotech Update- Pre-JPM
Biotech enters the JPM with constructive but selective risk appetite: public equity windows are open intermittently, valuation dispersion remains wide, and financing is available for differentiated clinical assets while earlier or “me-too” stories still struggle to clear diligence and pricing. The macro backdrop is supportive relative to the prior two years, where markets are rewarding […]
December 8th Biotech Update
Over the past two weeks, the biotech market has been shaped by a mix of both supportive macro forces and pockets of volatility tied to shifting risk sentiment. Cooling inflation data and growing expectations for rate cuts have provided a constructive backdrop, improving access to capital and lifting appetite for higher-beta sectors such as biotech. […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
